ENDODIAG

Founded in 2011, Endodiag is specialized in the development of products and services aimed at improving the diagnosis of endometriosis, a complex and poorly known disease, affecting yet 10% of women of reproductive age (over 180 million patients worldwide!). Located in Evry, France, within Genopole, the French largest Biocluster, the company leverages the experience of its scientific cofounders who have been working in this field for over 20 years and a network of major hospital centres both in France and abroad. Although endometriosis is a major cause of subfertility (40% of affected patients are infertile) and chronic pain, it takes an average 8 to 10 years between the onset of the disease and its diagnosis, currently only achieved through surgery. With its EndoGram® prognosis program, Endodiag contributes to improving current diagnostic practice by providing additional biological information for a personalized medical and therapeutic management for each patient. In parallel, the company develops a new non-invasive diagnostic test making endometriosis detection much easier and faster. Finally, Endodiag offers drug testing services to pharmaceutical companies enabling them to make early in-vitro evaluation of drug efficacy of cell lines and patient-derived cell cultures. In 2013, Endodiag actively contributed to the launch of oz2020, the first Endometriosis Observatory in France (www.oz2020.com). This observatory will help gather precise epidemiologic data on the disease and patients’ quality of life in order to advance and support scientific research, but also to raise endometriosis awareness. Learn more about Endodiag at www.endodiag.com